#1 Clinical Trials Search in Europe

Eptacog Alfa (Activated)

This article explores the use of Eptacog Alfa (Activated), also known as recombinant Factor VIIa or NovoSeven®, in clinical trials for various bleeding disorders. These trials investigate the drug’s safety, efficacy, and pharmacokinetics in conditions such as hemophilia with inhibitors, Glanzmann’s thrombasthenia, and intracerebral hemorrhage. The studies aim to evaluate the drug’s effectiveness in controlling bleeding episodes, its use in surgical settings, and its potential for prophylactic treatment.

Table of Contents

What is Eptacog Alfa (Activated)?

Eptacog alfa (activated) is a medication used to treat and prevent bleeding in certain medical conditions. It is also known by several other names, including:

  • Activated recombinant human factor VII
  • rFVIIa
  • NovoSeven®
This medication is a laboratory-made version of a protein that naturally occurs in the body and helps with blood clotting.[1]

Conditions Treated

Eptacog alfa (activated) is primarily used to treat bleeding disorders, including:

  • Hemophilia A and B with inhibitors: These are inherited conditions where the blood doesn’t clot properly. “With inhibitors” means that the patient’s body has developed antibodies that make standard treatments less effective.[2][3]
  • Glanzmann’s thrombasthenia: This is a rare genetic disorder that affects platelets, which are blood cells involved in clotting.[4]
  • Acquired bleeding disorders: These are bleeding problems that develop later in life, rather than being inherited.[5]
Additionally, research is being conducted on its use in other situations where controlling bleeding is crucial, such as during certain types of surgery or in cases of brain hemorrhage (bleeding in the brain).[6][5]

How It Works

Eptacog alfa (activated) works by mimicking a natural protein in your body called Factor VII. When activated, it helps your blood form clots more effectively. This is particularly useful in patients whose natural clotting mechanisms are impaired, such as those with hemophilia.[2]

Administration

Eptacog alfa (activated) is typically administered through intravenous (IV) injection, which means it’s given directly into a vein. The dosage and frequency of administration can vary depending on the specific condition being treated and the individual patient’s needs. For example:

  • For treating bleeding episodes in hemophilia patients, it may be given as a single high dose or as multiple smaller doses over time.[2]
  • For preventing bleeding during surgery in patients with bleeding disorders, it may be given before, during, and after the procedure.[7]
Always follow your healthcare provider’s instructions regarding dosage and administration.

Effectiveness

Research has shown that eptacog alfa (activated) can be effective in managing bleeding in various conditions:

  • In patients with hemophilia A or B with inhibitors, it has been shown to effectively stop or prevent bleeding episodes.[3]
  • For patients with Glanzmann’s thrombasthenia, it has been effective in controlling bleeding during episodes and in preventing bleeding during surgery or childbirth.[4]
  • Studies have also explored its use in reducing blood loss during certain types of surgery.[6]
The effectiveness can vary from patient to patient, and your healthcare provider will monitor your response to the treatment.

Safety and Side Effects

While eptacog alfa (activated) is generally considered safe when used as directed, like all medications, it can have side effects. The most serious potential side effect is the formation of blood clots in unintended places (thrombosis). This is why the medication is carefully monitored, especially in surgical settings.[4][6] Other possible side effects may include:

  • Fever
  • Headache
  • Nausea or vomiting
  • Skin reactions at the injection site
Always report any unusual symptoms or side effects to your healthcare provider.

Ongoing Research

Researchers continue to study eptacog alfa (activated) to better understand its effects and explore new potential uses. Some areas of ongoing research include:

  • Its use in treating intracerebral hemorrhage (bleeding in the brain)[5]
  • Optimizing dosing strategies for different conditions and patient groups[2]
  • Long-term safety and effectiveness in various bleeding disorders[8]
  • Its potential role in reducing blood loss during complex surgeries[6]
These ongoing studies help healthcare providers better understand how to use this medication effectively and safely.

Aspect Details
Drug Name Eptacog Alfa (Activated), also known as recombinant Factor VIIa or NovoSeven®
Main Conditions Studied Hemophilia A and B with inhibitors, Glanzmann’s thrombasthenia, Acute intracerebral hemorrhage
Primary Objectives Evaluate safety, efficacy, pharmacokinetics, and pharmacodynamics
Administration Methods Intravenous injection, various dosing regimens (single and multiple doses)
Key Outcome Measures Bleeding resolution, pain relief, adverse events, quality of life
Special Techniques Thromboelastography (TEG), Thromboelastometry (ROTEM)
Study Designs Observational studies, registries, non-interventional studies
Geographical Scope Studies conducted in Europe, North and South America, Asia (including Japan)

FAQ

  • What is Eptacog Alfa (Activated)? Eptacog Alfa (Activated) is a recombinant form of human Factor VIIa, also known as NovoSeven®. It is used to treat and prevent bleeding in patients with certain blood clotting disorders.
  • What conditions are being studied with Eptacog Alfa (Activated)? Clinical trials are investigating its use in hemophilia A and B with inhibitors, Glanzmann's thrombasthenia, and acute intracerebral hemorrhage.
  • How is Eptacog Alfa (Activated) administered? It is typically administered intravenously (by injection into a vein) at various doses depending on the condition and study protocol.
  • What are the main outcomes being measured in these trials? The trials are primarily measuring the drug's effectiveness in stopping bleeding, its safety profile, and its impact on patients' quality of life.
  • Are there any long-term studies on Eptacog Alfa (Activated)? Yes, some studies, such as the one in Japan, are designed to collect data on the drug's long-term safety and effectiveness over a period of up to 10 years.

Ongoing Clinical Trials on Eptacog Alfa (Activated)

  • Study on the Safety and Effectiveness of Emicizumab for Patients with Type 3 Von Willebrand Disease

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Poland +2

  • Study on Emicizumab and Drug Combination for Patients with Haemophilia A and FVIII Inhibitors

    Recruiting

    3 1 1 1
    Investigated drugs:
    Bulgaria Croatia Finland Germany Norway Spain +1

  • Study on Eptacog Alfa for Treating Acute Hemorrhagic Stroke in Patients with Brain Bleeding

    Recruiting

    3 1 1
    Investigated drugs:
    Germany Spain

Glossary

  • Eptacog Alfa (Activated): A recombinant form of human coagulation Factor VIIa used to treat and prevent bleeding in certain blood disorders.
  • Hemophilia: A genetic disorder that impairs the body's ability to make blood clots, leading to excessive bleeding.
  • Inhibitors: Antibodies that neutralize clotting factors, making standard treatments less effective in hemophilia patients.
  • Glanzmann's Thrombasthenia: A rare genetic platelet disorder that affects blood clotting.
  • Intracerebral Hemorrhage: Bleeding within the brain tissue, a severe form of stroke.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, and elimination.
  • Pharmacodynamics: The study of a drug's effects on the body, including its mechanism of action and relationship between drug concentration and effect.
  • Prophylaxis: Preventive treatment to stop or reduce the frequency of bleeding episodes.
  • Thromboelastography (TEG): A method of testing the efficiency of blood coagulation.
  • Adverse Event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.

References

  1. https://clinicaltrials.gov/study/NCT00703911
  2. https://clinicaltrials.gov/study/NCT01949792
  3. https://clinicaltrials.gov/study/NCT00882778
  4. https://clinicaltrials.gov/study/NCT01876745
  5. https://clinicaltrials.gov/study/NCT00266006
  6. https://clinicaltrials.gov/study/NCT00102037
  7. https://clinicaltrials.gov/study/NCT01579968
  8. https://clinicaltrials.gov/study/NCT01579955